EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against TESARO, Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of TESARO, Inc. (NASDAQ:TSRO) resulting from allegations that TESARO may have issued materially misleading business information to the investing public.

On January 12, 2018, TESARO announced it had updated the U.S. labeling for VARUBI® (rolapitant), indicated for the prevention of delayed nausea and vomiting associated with chemotherapy in adults, after there had been reports of “[a]naphylaxis, anaphylactic shock and other serious hypersensitivity reactions . . . in the postmarketing setting, some requiring hospitalization.” Tesaro further stated it “has issued a Dear Healthcare Professional (DHCP) letter.” On this news, shares of TESARO fell $4.07 per share or over 5% to close at $65.52 per share on January 16, 2018.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by TESARO investors. If you purchased shares of TESARO, please visit the firm’s website at http://www.rosenlegal.com/cases-1270.html or more information. You may also contact Phillip Kim or Daniel Sadeh of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or dsadeh@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180116006824/en/